| Literature DB >> 23840247 |
Chiu-Mei Chen1, Chien-Ying Lee, Po-Jung Lin, Chin-Lang Hsieh, Hung-Che Shih.
Abstract
Purpose. To explore the effects of SiJunZiTang (SJZT) on central neurotransmitters and the inhibition of HCl hypersecretion, along with the role of the vagus nerve. From this, the effects of SJZT and its constituent ingredients on inhibiting stress-induced peptic ulcers will be determined. Methods. Methods used to determine SJZT's effectiveness included (1) measuring the antipeptic ulcer effects of varying combinations of the constituents of SJZT; (2) evaluations of monoamine (MA) level in the brain; and (3) measuring the effects of longer-term SJZT treatment. Results. Comparing the control and experimental groups where the rats' vagus nerves were not cut after taking SJZT orally (500 mg/kg and 1000 mg/kg), the volume of enterogastric juice, free HCl and total acidity all reduce dose-dependently. The group administered SJZT at 1000 mg/kg showed significant reductions (P < 0.05). For the experimental groups where the vagus nerves were cut, a comparison with the control group suggests that the group receiving SJZT (500 mg/kg) orally for 21 days demonstrated a cure rate of 34.53%. Conclusion. The results display a correlation between the therapeutic effects of SJZT on stress-induced peptic ulcers and central neurotransmitter levels. Further to this, SJZT can inhibit the hypersecretion of HCl in the stomach, thus inhibiting stress-induced peptic ulcers.Entities:
Year: 2013 PMID: 23840247 PMCID: PMC3694386 DOI: 10.1155/2013/186076
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Procedures for the preparation of SJZT.
Figure 2Flow chart of the preparation process for monoamine.
Effects of SJZT on volume of gastric juice, free HCl, and total acidity of gastric acid for rats of vagus nerves were cut and not cut.
| Types | Groups | UN-vagotomy | Vagotomy |
|---|---|---|---|
| Volume | Dist. H2O 5.0 mL/kg | 9.92 ± 0.62 mL | 3.82 ± 0.30 mL |
| SJZT 500 mg/kg | 6.21 ± 0.93 mL | 1.82 ± 0.52 mL | |
| SJZT 1000 mg/kg | 5.43 ± 0.47* mL | 2.89 ± 0.64 mL | |
|
| |||
| Free HCl | Dist. H2O 5.0 mL/kg | 49.67 ± 3.11 mEq/mL | 1.73 ± 0.51 mEq/mL |
| SJZT 500 mg/kg | 25.06 ± 2.80 mEq/mL | 1.65 ± 0.63 mEq/mL | |
| SJZT 1000 mg/kg | 21.02 ± 2.02* mEq/mL | 0.91 ± 0.26* mEq/mL | |
|
| |||
| Total acidity | Dist. H2O 5.0 mL/kg | 81.17 ± 4.08 mEq/mL | 7.18 ± 0.87 mEq/mL |
| SJZT 500 mg/kg | 74.03 ± 2.55 mEq/mL | 6.59 ± 0.96 mEq/mL | |
| SJZT 1000 mg/kg | 39.31 ± 3.06* mEq/mL | 7.82 ± 0.82 mEq/mL | |
*P < 0.05; N = 6; mean ± S.E.; peroral, control group: Dist. H2O 5.0 mL/kg (B.W.)
Effects of SJZT and relevant ingredients on stress-induced peptic ulcers.
| Number | Groups | Results |
|---|---|---|
| a | 5.0 mL/kg Dist. H2O | 40.57 ± 0.78 mm |
| b | SJZT | 14.10 ± 0.51 mm*** |
| c |
| 48.58 ± 1.42 mm |
| d |
| 20.29 ± 0.69 mm* |
| e |
| 15.32 ± 0.64 mm** |
| f |
| 21.50 ± 0.55 mm* |
| g |
| 41.59 ± 1.06 mm |
| h |
| 34.99 ± 0.96 mm |
| i |
| 23.85 ± 0.31 mm |
| j |
| 46.78 ± 0.53 mm |
| k |
| 15.94 ± 0.29 mm* |
| l |
| 114.66 ± 1.33 mm |
*P < 0.05; **P < 0.01; ***P < 0.001; N = 6; mean (mm) ± S.E.
Figure 3Effects of SJZT and relevant ingredients on stress-induced peptic ulcers.
Therapeutic effects of continuous administration of SJZT on peptic ulcers.
| Models | Ulcerative length | Ratio | Amount |
|---|---|---|---|
| Ulcer induced by water | 120.17 ± 2.23 mm | 100% |
|
| SJZT (500 mg/kg) P.O. for 14 days | 97.50 ± 1.88 mm | 81.25% |
|
| SJZT (500 mg/kg) P.O. for 21 days | 78.67 ± 1.47 mm* | 65.47% |
|
*P < 0.05; Mean (mm) ± S.E.; P.O. means per os or oral administration; Control group: Ulcer induced by water immersion for 7 days.
(a)
| Brain | Reagents | N A | D A | 5-HT |
|---|---|---|---|---|
| Cortex | Dist. H2O 5.0 mL/kg | 40.9 ± 2.3 | 102.4 ± 3.7 | 50.3 ± 2.2 |
| SJZT 500 mg/kg | 31.3 ± 1.4 | 86.2 ± 3.3 | 34.1 ± 4.9 | |
| SJZT1000 mg/kg | 17.3 ± 1.1* | 62.8 ± 5.6* | 25.9 ± 2.8* | |
|
| ||||
| Brain | Dist. H2O 5.0 mL/kg | 47.9 ± 0.9 | 131.7 ± 3.4 | 57.2 ± 3.1 |
| SJZT 500 mg/kg | 41.6 ± 0.3 | 79.4 ± 1.9* | 39.2 ± 0.8* | |
| SJZT 1000 mg/kg | 35.6 ± 0.5 | 77.8 ± 2.1* | 35.1 ± 1.8* | |
*P < 0.05; mean ± S.E.; N = 6; peroral, ng/g (wet weight); control group: Dist. H2O 5.0 mL/kg (B.W.).
(b)
| Brain | Reagents | HVA | 5-HIAA | VMA |
|---|---|---|---|---|
| Cortex | Dist. H2O 5.0 mL/kg | 7.2 ± 0.4 | 48.2 ± 2.5 | 10.2 ± 0.9 |
| SJZT 500 mg/kg | 8.1 ± 0.2 | 48.2 ± 1.7 | 10.9 ± 1.8 | |
| SJZT1000 mg/kg | 6.8 ± 0.3 | 21.3 ± 0.8* | 10.1 ± 1.3 | |
|
| ||||
| Brain | Dist. H2O 5.0 mL/kg | 7.2 ± 0.4 | 48.2 ± 2.5 | 10.2 ± 0.9 |
| SJZT 500 mg/kg | 7.8 ± 0.7 | 80.4 ± 1.6* | 8.9 ± 0.2 | |
| SJZT 1000 mg/kg | 6.6 ± 0.4 | 73.8 ± 1.0 | 7.6 ± 0.3 | |
*P < 0.05; mean ± S.E.; N = 6; peroral, ng/g (wet weight).